Loading...
Cytokinetics, Incorporated
CYTK•NASDAQ
Healthcare
Biotechnology
$37.18
$-0.13(-0.35%)
Cytokinetics, Incorporated (CYTK) Financial Performance & Income Statement Overview
Review Cytokinetics, Incorporated’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
145.34%
↑ 145.34%
Operating Income Growth
-8.07%
↓ 8.07%
Net Income Growth
-12.03%
↓ 12.03%
Operating Cash Flow Growth
4.45%
↑ 4.45%
Operating Margin
-2943.30%
↓ 2943.30%
Gross Margin
-1359.51%
↓ 1359.51%
Net Profit Margin
-3201.47%
↓ 3201.47%
ROE
801.26%
↑ 801.26%
ROIC
-51.22%
↓ 51.22%
Cytokinetics, Incorporated (CYTK) Income Statement & Financial Overview
Review Cytokinetics, Incorporated's (CYTK) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $16.93M | $463000.00 | $249000.00 | $835000.00 |
| Cost of Revenue | $93.63M | $84.61M | $2.41M | $2.33M |
| Gross Profit | -$76.70M | -$84.15M | -$2.16M | -$1.50M |
| Gross Profit Ratio | -$4.53 | -$181.75 | -$8.66 | -$1.79 |
| R&D Expenses | $0.00 | $463000.00 | $77.19M | $79.24M |
| SG&A Expenses | $62.34M | $56.65M | $50.82M | $45.50M |
| Operating Expenses | $62.34M | $141.26M | $128.01M | $124.74M |
| Total Costs & Expenses | $155.97M | $141.26M | $130.42M | $127.07M |
| Interest Income | $15.01M | $17.05M | $11.55M | $7.91M |
| Interest Expense | $22.59M | $22.30M | $24.30M | $17.32M |
| Depreciation & Amortization | $2.38M | $2.41M | $2.41M | $2.33M |
| EBITDA | -$125.04M | -$138.25M | -$116.61M | -$115.99M |
| EBITDA Ratio | -$7.39 | -$298.59 | -$468.33 | -$138.91 |
| Operating Income | -$139.04M | -$140.80M | -$130.17M | -$126.23M |
| Operating Income Ratio | -$8.21 | -$304.11 | -$522.78 | -$151.18 |
| Other Income/Expenses (Net) | -$10.98M | -$19.74M | -$13.15M | -$9.41M |
| Income Before Tax | -$150.02M | -$160.54M | -$143.32M | -$135.64M |
| Income Before Tax Ratio | -$8.86 | -$346.75 | -$575.57 | -$162.45 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $2.29M |
| Net Income | -$150.02M | -$160.54M | -$143.32M | -$135.64M |
| Net Income Ratio | -$8.86 | -$346.75 | -$575.57 | -$162.45 |
| EPS | -$1.26 | -$1.36 | -$1.31 | -$1.33 |
| Diluted EPS | -$1.26 | -$1.36 | -$1.31 | -$1.33 |
| Weighted Avg Shares Outstanding | $118.08M | $117.69M | $109.24M | $101.92M |
| Weighted Avg Shares Outstanding (Diluted) | $118.08M | $117.69M | $109.24M | $101.92M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan